Major depressive disorder (MDD), also referred to as depression, is one of the most common
psychiatric disorders with a high economic burden. The etiology of depression is still not …

The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Objectif: Les patients souffrant de trouble dépressif majeur (TDM) ont souvent une réponse
limitée aux médicaments de première et de deuxième intention, donc de nouveaux …

Background The inflammation and oxidative stress (OS) have been considered crucial
components of the pathogenesis of depression. Edaravone (EDA), a free radical scavenger …

Abstract (R, S)-ketamine elicits rapid-acting and sustained antidepressant actions in
treatment-resistant patients with depression.(R)-ketamine produces longer-lasting …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Depression is a polygenic trait that causes extensive periods of disability. Previous genetic
studies have identified common risk variants which have progressively increased in number …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Inflammatory bowel disease (IBD), which mainly includes ulcerative colitis (UC) and Crohn's
disease (CD), is a group of chronic bowel diseases that are characterized by abdominal …

Objective: Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce
suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been …